Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?

Annals of surgical oncology - 1 Apr 2024

Polidorio Natália, Montagna Giacomo, Sevilimedu Varadan, Le Tiana, Morrow Monica

Abstract excerpt

BACKGROUND: Breast cancer subtypes, distinguished by hormone receptor (HR) and HER2 status, have different clinicopathologic features. With recognition of the clinical relevance of HER2-low, there is debate as to whether this is a distinct subtype. Our study aimed to determine whether HER2-low breast cancers have specific clinicopathologic features that differ from those of HER2-negative and HER2-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to In Situ Hybridization, Fluorescence
Share to Phenotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 38158494
DOI: 10.1245/s10434-023-14800-w
PMCID: PMC11177575

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?PMID 38158494Read ↗

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Clinical Significance and Genetic Characteristics in HER2 Low Expression Tumors of Hormone Receptor Positive Breast Cancer PatientsSemantic proximity Read ↗

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.Semantic proximity Read ↗

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional AnalysisSemantic proximity Read ↗

Prognostic value of basal phenotype in HER2-overexpressing breast cancer.Semantic proximity Read ↗

Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.Semantic proximity Read ↗

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerSemantic proximity Read ↗

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.